TABLE 2.
Percent positivity and average MFIa values of 3Flex versus Abbott Architect SARS-CoV-2 IgG serological tests by days from symptom onset for 125 unique patients
| No. of days from symptom onset | Total no. (%) of tests | Abbott Architect SARS-CoV-2 IgG | 3Flex |
|||
|---|---|---|---|---|---|---|
| No. (%) of positive test results | No. (%) of positive test results | MFI avg (95% CI) |
||||
| Spike | RBD | Nucleocapsid | ||||
| ≤5 | 25 (100.0) | 8 (32.0) | 12 (48.0) | 4,637 (719–8,554) | 2,337 (355–4,319) | 6,578 (2,823–10,333) |
| 6–10 | 25 (100.0) | 13 (54.2)b | 17 (68.0) | 11,688 (5,053–18,324) | 6,283 (1,700–10,867) | 14,779 (6,111–23,477) |
| 11–15 | 25 (100.0) | 20 (80.0) | 21 (84.0) | 24,654 (15,358–33,950) | 14,378 (6,202–22,554) | 19,592 (12,242–26,941) |
| 16–20 | 25 (100.0) | 22 (91.6)b | 23 (92.0) | 23,202 (17,044–29,359) | 14,222 (9,185–19,258) | 25,534 (18,859–32,209) |
| ≥21 | 25 (100.0) | 23 (92.0) | 23 (92.0) | 27,010 (20,231–33,789) | 16,258 (10,727–21,789) | 22,591 (13,629–31,554) |
a
MFI, median fluorescent intensity.
b
One test had insufficient volume for the Abbott Architect SARS-CoV-2 IgG assay.